7/19/2024  9:59:59 PM Chg. +0.96 Volume Bid- Ask- Market Capitalization Dividend Y. P/E Ratio
111.65USD +0.87% 79,160
Turnover: 8.79 mill.
-Bid Size: - -Ask Size: - 44.41 bill.USD - 79.76

Business description

Dexcom, Inc. empowers people to take control of diabetes through innovative continuous glucose monitoring (CGM) systems. Headquartered in San Diego, California, Dexcom has emerged as a leader of diabetes care technology. By listening to the needs of users, caregivers, and providers, Dexcom simplifies and improves diabetes management around the world.
 

Management board & Supervisory board

CEO
Kevin Sayer
Management board
Jereme Sylvain, Andrew K. Balo, Barry Regan, Chad Patterson, Don Abbey, Jake Leach, Paul Flynn, Sadie Stern, Shelly Selvaraj, Steven R. Pacelli, Sumi Shrishrimal
Supervisory board
Kevin Sayer, Barbara E. Kahn, Bridgette Heller, Eric J. Topol, M.D., Jay Skyler, M.D., Karen Dahut, Kyle Malady, Mark Foletta, Nick Augustinos, Richard Collins, Steven R. Altman
 

Company data

Name: Dexcom Inc.
Address: 6340 Sequence Drive,San Diego, CA 92121, USA
Phone: +1-858-200-0200
Fax: -
E-mail: -
Internet: https://www.dexcom.com/
Industry: Biotechnology
Sector: Biotechnology
Sub sector: Biotechnology
End of financial year: 12/31
Free Float: -
IPO date: -

Investor relations

Name: Steve Pacelli
IR phone: -
IR Fax: -
IR e-mail: spacelli@dexcom.com

Company calendar

CW 30 | 7/25/2024 Interim Report 2nd Quarter/6 Months
 

Main Shareholders

Others
 
55.44%
Vanguard Group Inc
 
11.42%
Blackrock Inc.
 
8.57%
Baillie Gifford and Company
 
4.31%
State Street Corporation
 
4.27%
Sands Capital Management, LLC
 
3.38%
JP Morgan Chase & Company
 
3.27%
FMR, LLC
 
2.73%
Capital Research Global Investors
 
2.35%
Others
 
4.26%